ABSTRACT The stability of the 37− amino acid peptide pramlintide, in aqueous solution, was studied as a function of pH and temperature. Samples of pramlintide formulated as a parenteral product were exposed to elevated temperatures and to realistic storage conditions for as long as 30 months. Pramlintide degradation was monitored by three high-performance liquid chromatography (HPLC) methods: a reversedphase (RP-HPLC) and a strong-cation exchange (SCX-HPLC) method for percentage purity determination by area normalization, plus a second RP-HPLC method for potency determination versus external standards. The pH-rate profile for pramlintide shows increasing degradation rate constants with increasing pH over the range pH = 3.5 to 5.0. The Arrhenius expression for pramlintide degradation at pH = 4.0 over the temperature range 5°C to 50° C is ln(k 0 )= 37.39 -21.900/RT, where k 0 is the zero-order rate constant (in %/mo) for pramlintide degradation. The pramlintide parenteral product formulated at pH = 4.0 is extremely stable, with percentage purity and percentage potency loss of only approximately 2% over 30 months at 5°C. The formulated pramlintide drug product has acceptable shelf life for long-term storage at 5°C and up to a 30-day patient use when stored at ambient temperature.
INTRODUCTION
Amylin is a 37− amino acid peptide hormone that is produced in the pancreas and co-secreted with insulin in response to elevated serum glucose levels [1] [2] [3] . Pramlintide is a synthetic analog of amylin that retains the biological activity of the hormone while offering superior physical and chemical properties that facilitate development of a stable drug product for parenteral administration [ 4] . Pramlintide is being evaluated as a drug candidate for treating people with type 1 and insulin-using type 2 diabetes. [5] [6] [7] Figure 1 shows the pramlintide amino acid sequence with the disulfide bridge between cysteines 2 and 7 and highlights the amino acid differences between pramlintide and amylin.
All of the carboxyl groups in pramlintide are amidated, rendering the molecule cationic (protonated lysine, histidine, and arginine) at acidic pH. Pramlintide may be isolated as a lyophilized salt with acetate as the counterion. An injectable, multi-dose, liquid formulation for pramlintide drug product has been developed. The formulation uses pramlintide at 0.30 to 1.0 mg/mL concentrations and m-cresol as an antimicrobial preservative. Previous investigations have identified the significant pramlintide hydrolysis products [ 8] and demonstrated the performance of stabilityindicating reversed-phase high-performance chromatography (RP-HPLC) and strong cation exchange (SCX-HPLC) analytical test methods [9] .
This report details the kinetics of pramlintide degradation as a function of pH (range = 3.5 to 5.0) and temperature (range = 5 to 50°C). Also reported herein are results of potency and purity determinations of pramlintide injection drug product samples maintained as long as 30 months at 5° C.
MATERIALS AND METHODS

Test Articles
Sterile pramlintide injection drug product samples were prepared by aseptic processing at 0.3 or 0.6 mg/ml in pH 3.5 to pH 5.0 aqueous acetate buffer with m-cresol added as antimicrobial preservative. The samples were stored in 5-mL glass vials with bromobutyl rubber closures.
Working Reference Standard
Pramlintide working reference standard solutions were prepared at 0.5 mg/mL in pH 4.0, 30 mM acetate buffer. m-Cresol working reference standards were prepared at 0.225% (w/w) in pH 4.0, 30 mM acetate buffer.
Drug Product Samples
For both the RP-and SCX-HPLC percentage purity methods, pramlintide injection samples were subjected to a solid-phase extraction step to remove mannitol and m-cresol, as previously described [9] . For the RP-HPLC potency method, pramlintide injection samples were directly injected without additional workup. Table 1 shows operating parameters for this test method, Table 2 shows mobile phase compositions, and Table 3 shows the gradient profile. 
Test System and Reagents
RP-HPLC Determinations of Pramlintide Potency and m-Cresol Concentration
Calculations
Because the extent of pramlintide percentage purity loss with time was low under all conditions studied (typically less than approximately 15% decrease from initial values), treating the decrease in percentage purity values by either zero-order or pseudo-first-order kinetic models will yield essentially identical comparisons. For simplicity, this report employs a zero-order model according to equation 1:
where %P is the percentage purity at time t, relative to the initial percentage purity, %Purity is determined by area normalization using either the RP-HPLC %Purity method or the SCX-HPLC %Purity method, I 0 is the regression intercept, and k 0 is the zero-order degradation rate constant (regression slope) in %-mo -1 . Note that for the convention employed in equation 1, decreasing % of Initial Purity values with time, corresponds to a negative k 0 value.
Similarly, for loss in potency, this report employs a zero-order model according to equations 2 and 3:
%LS = 100*(LS t ÷ ÷ LS t=0 ) = I 0 + k 0 *t
where LS is the drug product potency relative to the label strength (label strength is either 0.3 mg/mL or 0.6 mg/mL), % LS is the label strength at time t, expressed as a percentage of initial LS, I 0 is the regression intercept, and k 0 is the zero-order degradation rate constant (regression slope) in %-mo -1 .
RESULTS
Control Experiments
Suitable control experiments demonstrated that formulated pramlintide injection pH and m-cresol were essentially invariant with storage time and temperatures under the conditions studied. There were no changes in visual appearance and no significant changes in the amount of visible or subvisible particulate matter. Furthermore, pramlintide degradation rate constants were independent of pramlintide over the concentration range 0.3 to 0.6 mg/mL. Four different pramlintide injection drug product lots were used for these determinations, all made to pH = 4.0. The k 0 values were determined by leastsquares linear regression analysis according to equation 1. Because the 3 analytical test methods employed showed essentially equivalent stability specificity ( vide supra), Table 4 shows data determined by the SCX-HPLC %Purity method only. Table 4 
Time and Temperature Dependence of %Purity and Potency Loss for
where A is the Arrhenius frequency factor, E a is the activation energy (cal/mol), T is absolute temperature (° K), and R is the gas constant (1.98 cal/mol-° ). conditions, but excludes the k 0 value for the 5° C condition because the rate constant at 5° C is not statistically significantly different from zero. The figure shows that pramlintide degradation kinetics adhere well to equation (4) over the temperature range studied. From Figure 4 , the Arrhenius frequency factor is 37.394 and the activation energy (slope*R) is 21 900 cal/mol.
pH Effect on Pramlintide Degradation
Kinetics at 40°° C Table 5 shows k 0 values for pramlintide injection samples formulated at pH = 3.5, 4.0, 4.5, and 5.0 and maintained at 40° C. The k 0 values were determined by the SCX-HPLC %Purity method and calculated according to equation 1. Table 5 shows that pramlintide degradation rate constant (k 0 ) values increase approximately 3-fold with increasing pH over the range studied. Table 4 .
DISCUSSION
It has been reported that hydrolytic backbone cleavage and deamidation reactions predominate for peptide samples maintained at acidic pH [10] [11] [12] [13] [14] . We previously found that backbone cleavage and deamidation are the primary pathways for pramlintide degradation at pH = 4.0 [8] .
This investigation focused on determining pramlintide hydrolysis kinetics over the pH range 3.5 to 5.0 and the temperature range 5°C to 50° C.
The analytical techniques used to monitor pramlintide hydrolysis included two methods for pramlintide %Purity that employ orthogonal separation modes, namely an RP-HPLC %Purity method and an SCX-HPLC %Purity method [ 9] . This investigation also utilized an RP-HPLC potency method that quantitated pramlintide versus external standards (rather than by internal area normalization). The RP-HPLC potency method provided a third axis of orthogonality for pramlintide degradation testing and is useful for detecting nonspecific physical losses (such as surface adsorption or aggregation) that might go undetected by the %Purity methods. Figure 2 shows that the RP-HPLC and SCX-HPLC methods provide essentially identical %Purity information for samples formulated at pH = 4.0 and maintained at 5°C to 40 ° C. The equivalence in degradation rates is consistent with our previous observationsthat the RP-HPLC and SCX-HPLC %Purity methods are highly selective and resolve all major degradation products from intact pramlintide [9] . Figure 2 also shows good adherence to the zero-order kinetic model chosen for this study. The pH-rate dependence seen for pramlintide over the range pH = 3.5 to 5.0 shows that k 0 values increased approximately 3-fold over the range investigated.
Finally, Figures 2 and 3 demonstrate that pramlintide injection samples formulated at pH = 4.0 are extremely stable under refrigerated storage, with %Purity and potency losses less than 2% over a 30-month period. Similarly, at 25° C (the anticipated patient use condition) the pH = 4.0 formulation offers excellent stability with %Purity and potency losses less than approximately 2% over a 1-month storage interval.
